News Vector Science and Therapeutics Corp.

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Delayed Toronto S.E. Other stock markets 12:16:15 2026-08-06 EDT			5-day change	1st Jan Change
1.600 ^CAD	-2.44%		+1.28%	+3,060.00%

07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI

All News

Mentions Relevance

07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-27	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-24	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
07-17	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
07-17	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist	AQ
07-15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
07-15	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ
07-08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
07-07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
07-07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio	AQ
06-30	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI
06-30	Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform	AQ
06-22	Gary Payton II Named Chief Athletic Ambassador of Valor	AQ
06-15	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform	AQ
06-12	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform	AQ
06-12	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform	CI
06-08	Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor	AQ
06-08	Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors	CI
06-02	Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy	AQ
05-13	Vector Science and Therapeutics enters option to buy up to 15% of Lyogenesis Plus for up to $1 million	RE
05-13	Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing	AQ
05-11	Vector Science & Therapeutics Inc. Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC	CI